Status:
COMPLETED
A Study of Treatment Patterns and Clinical Outcomes of Psoriasis in Japan
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Psoriasis
Eligibility:
All Genders
20+ years
Brief Summary
The purpose of this study is to understand current real-world treatment patterns and clinical outcomes, reasons for switching treatment, and participant characteristics using each systemic psoriasis t...
Eligibility Criteria
Inclusion
- Diagnosis of psoriasis
- Can be followed for at least 2 years
- Treated with any of the following systemic therapy for psoriasis at time of follow-up start: Tumor Necrosis Factor (TNF) inhibitors (infliximab, adalimumab, and certolizumab pegol), Interleukin (IL)-12/23 inhibitors (ustekinumab), IL-23 inhibitors(guselkumab, risankizumab, and tildrakizumab), IL-17 inhibitors (secukinumab, ixekizumab, and brodalumab), Apremilast, Methotrexate, Cyclosporine, Etretinate
Exclusion
- Enrolled in any clinical trials for psoriasis in their follow-up period
- Developed psoriatic arthritis, guttate psoriasis, erythrodermic psoriasis, and pustular psoriasis at time of start date
- Treated with any of the following systemic therapy before they were diagnosed with psoriasis: TNF inhibitors (infliximab, adalimumab, and certolizumab pegol), IL-12/23 inhibitors (ustekinumab), IL-23 inhibitors(guselkumab, risankizumab, and tildrakizumab), IL-17 inhibitors (secukinumab, ixekizumab, and brodalumab), Apremilast, Methotrexate, Cyclosporine, Etretinate
Key Trial Info
Start Date :
June 25 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 8 2021
Estimated Enrollment :
114 Patients enrolled
Trial Details
Trial ID
NCT04826536
Start Date
June 25 2021
End Date
October 8 2021
Last Update
June 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Minato-ku, Tokyo, Japan, 1070052